Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy

Parent Project Muscular Dystrophy’s proposed guidance gives detail on biomarkers and clinical trial designs for the beleaguered field, but most importantly addresses benefit-risk assessment – which is FDA’s underlying ambition for the patient-focused drug development initiative.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America